Detalhe da pesquisa
1.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Nature
; 623(7989): 1053-1061, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37844613
2.
Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.
Future Oncol
; 14(5): 443-448, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29318908
3.
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
Eur Urol Oncol
; 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38429210
4.
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel.
Cancers (Basel)
; 14(19)2022 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36230681
5.
Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes.
Cancers (Basel)
; 13(19)2021 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638444
6.
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Cancer Res
; 81(24): 6207-6218, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34753775
7.
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Eur Urol
; 79(2): 200-211, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176972
8.
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Cancer Res
; 79(10): 2580-2592, 2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30952632
9.
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Eur Urol
; 76(5): 676-685, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31036442
10.
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
Ther Adv Med Oncol
; 10: 1758835918786658, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30023007
11.
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
Eur J Cancer
; 89: 56-63, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29227818
12.
Breast cancer in BRCA mutation carriers: medical treatment.
Minerva Ginecol
; 68(5): 557-65, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26799758
13.
Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.
Expert Opin Investig Drugs
; 25(4): 393-403, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26863927
14.
Clinical utility of exemestane in the treatment of breast cancer.
Int J Womens Health
; 7: 551-63, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26064072
15.
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Expert Opin Investig Drugs
; 24(3): 421-31, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25645727
16.
Linifanib: current status and future potential in cancer therapy.
Expert Rev Anticancer Ther
; 15(6): 677-87, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25936222
17.
Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Cancer Res
; 80(10): 2072, 2020 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414837
18.
Elucidating Durable Responses to Immune Checkpoint Inhibition.
Eur Urol
; 78(4): 639-641, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32653323
19.
2013 San Antonio Breast Cancer Symposium.
Expert Opin Pharmacother
; 15(8): 1191-5, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24697336